Aushon Biosystems this week said it will collaborate with Peking University Cancer Hospital to develop protein biomarkers for the diagnosis of liver metastases of colorectal cancer.
Under the agreement, Aushon will use its protein biomarker detection platform to develop biomarkers to predict liver metastases of colorectal cancer, as well as stratification biomarkers for radio-chemotherapy patients.
The announcement follows on a deal Aushon signed in November with Chinese drug development company LightArray. At that time Aushon CEO Pete Honkanen told ProteoMonitor the agreement would give the company a foothold in the Chinese market, allowing it to take advantage of what it expected would be increasing demand for its products from the country's domestic biotech firms and research organizations (PM 12/03/2010).
Because Chinese regulations forbid sending patient samples out of country, having a domestic laboratory presence is key for biotech companies looking to demonstrate their wares to potential Chinese customers, he noted.
The PUCH collaboration was initiated by the US Chinese Anti-Cancer Association, a non-profit organization of academic, commercial, and government entities launched in 2009 to facilitate collaborations between cancer researchers and physicians in the US and China.
Jin Gu, a professor and clinician at PUCH, will lead the research.